REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments…
TORONTO, ON / ACCESSWIRE / February 27, 2019 / Itoco Inc (OTC PINK: ITMC), has signed a letter of intent…
- Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior…
Uses proprietary chemoprobe technology to demonstrate target engagement, key to drug development and rational dosing Useful to identify interaction partners…
PHASE II CLINICAL TRIAL ON PERSISTENT CHRONIC COUGH HAMBURG, GERMANY / ACCESSWIRE / February 28, 2019 / Evotec AG (OTC…
Theralase Achieves Third Place in the Clean Technology and Life Sciences Category on the 2019 TSX Venture 50 TM TORONTO,…
VANCOUVER, BC / ACCESSWIRE / February 28, 2019 / EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the ''Company'') provides…
DALLAS, TX / ACCESSWIRE / February 26, 2019 / What if there was a way to prioritize drug discovery by…
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / February 27, 2019 / MorphoSys AG (FSE: MOR) (NASDAQ: MOR) announced today that…
Data identifies a simple blood test that predicts clinical response to pelareorep CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE…